358 related articles for article (PubMed ID: 26538546)
21. Lipoprotein(a) accelerates atherosclerosis in uremic mice.
Pedersen TX; McCormick SP; Tsimikas S; Bro S; Nielsen LB
J Lipid Res; 2010 Oct; 51(10):2967-75. PubMed ID: 20584868
[TBL] [Abstract][Full Text] [Related]
22. Emerging therapeutic agents to lower lipoprotein (a) levels.
Kolski B; Tsimikas S
Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
[TBL] [Abstract][Full Text] [Related]
23. Lipoprotein(a) catabolism: a case of multiple receptors.
McCormick SPA; Schneider WJ
Pathology; 2019 Feb; 51(2):155-164. PubMed ID: 30595508
[TBL] [Abstract][Full Text] [Related]
24. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
Nsaibia MJ; Mahmut A; Boulanger MC; Arsenault BJ; Bouchareb R; Simard S; Witztum JL; Clavel MA; Pibarot P; Bossé Y; Tsimikas S; Mathieu P
J Intern Med; 2016 Nov; 280(5):509-517. PubMed ID: 27237700
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein(a) Management: Pharmacological and Apheretic Treatment.
Hanssen R; Gouni-Berthold I
Curr Med Chem; 2017; 24(10):957-968. PubMed ID: 28078998
[TBL] [Abstract][Full Text] [Related]
26. Lipoprotein(a).
Kronenberg F
Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
[TBL] [Abstract][Full Text] [Related]
27. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
[TBL] [Abstract][Full Text] [Related]
28. Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.
Di Costanzo A; Indolfi C; Franzone A; Esposito G; Spaccarotella CAM
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834387
[TBL] [Abstract][Full Text] [Related]
29. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
[TBL] [Abstract][Full Text] [Related]
30. Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a).
Kosmas CE; Bousvarou MD; Papakonstantinou EJ; Tsamoulis D; Koulopoulos A; Echavarria Uceta R; Guzman E; Rallidis LS
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686428
[TBL] [Abstract][Full Text] [Related]
31. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
Saeed A; Virani SS
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
[TBL] [Abstract][Full Text] [Related]
32. Associations among serum lipoprotein(a) levels, apolipoprotein(a) phenotypes, and myocardial infarction in patients with extremely low and high levels of serum lipoprotein(a).
Saku K; Zhang B; Liu R; Shirai K; Arakawa K
Jpn Circ J; 1999 Sep; 63(9):659-65. PubMed ID: 10496479
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Lp(a): Is It the Future or Are We Ready Today?
Tselepis AD
Curr Atheroscler Rep; 2023 Oct; 25(10):679-689. PubMed ID: 37668953
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
Tada H; Takamura M; Kawashiri MA
J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
[TBL] [Abstract][Full Text] [Related]
35. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
Tsimikas S; Hall JL
J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
[TBL] [Abstract][Full Text] [Related]
37. Endothelium-dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a).
Rubanyi GM; Freay AD; Lawn RM
Endothelium; 2000; 7(4):253-64. PubMed ID: 11201523
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
39. Effects of dietary fat saturation on plasma lipoprotein(a) and hepatic apolipoprotein(a) mRNA concentrations in cynomolgus monkeys.
Brousseau ME; Ordovas JM; Nicolosi RJ; Schaefer EJ
Atherosclerosis; 1994 Mar; 106(1):109-18. PubMed ID: 8018102
[TBL] [Abstract][Full Text] [Related]
40. Recent lipoprotein(a) trials.
Wei T; Cho L
Curr Opin Lipidol; 2022 Dec; 33(6):301-308. PubMed ID: 36345866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
